Experience of using a fixed-dose combination of perindopril and amlodipine in the clinical practice settings: a real-world opportunity to increase antihypertensive therapy effectiveness
https://doi.org/10.15829/1560-4071-2013-5-44-49
Abstract
The paper presents the results of the studies on effectiveness and safety of a fixeddose combination of perindopril A and amlodipine (Prestans) in the real-world clinical practice settings in Russia and other countries. The focus is on the evidence of fast and strong antihypertensive action of this medication, its excellent tolerability, and increased therapy compliance. The evidence presented justifies a wider use of this fixed-dose combination of perindopril A and amlodipine in order to improve blood pressure control in hypertensive patients.
About the Authors
O. D. Ostroumova
A. I. Evdokimov Moscow State Medico-Stomatological University, I. M. Sechenov First Moscow Sate Medical University, Moscow, Russia
Russian Federation
Russian Federation
T. F. Guseva
A. I. Evdokimov Moscow State Medico-Stomatological University, I. M. Sechenov First Moscow Sate Medical University, Moscow, Russia
Russian Federation
Russian Federation
O. V. Bondarets
A. I. Evdokimov Moscow State Medico-Stomatological University, I. M. Sechenov First Moscow Sate Medical University, Moscow, Russia
Russian Federation
Russian Federation
References
1. Mathers C., Stevens G., Mascarenhas M. Global health risks: mortality and burdenof disease attributable to selected major risks. Geneva, Switzerland: World Health Organization; 2009.
2. Diagnostics and treatment of arterial hypertension. Russian recommendations (fourth edition). System hypertensions 2010; 3:5–26. (Диагностика и лечение артериальной гипертензии. Российские рекомендации (четвертый пересмотр). Системные гипертензии 2010; 3:5–26).
3. Dahlof B., Sever P. S., Poulter N. R., et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in Anglo-Scandinavian Cardiac Outcomes Trial — Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentral randomized controlled trial. Lancet 2005; 366:895–906.
4. Karpov Yu. A., Deev A. D. on behalf of doctors — participants of the program PRORYV. Uncontrolled Arterial Hypertension — New Possibilities in Solving Problems of Increasing the Effectiveness of Treatment. Cardiology 2012; 2:29–35. (Карпов Ю. А., Деев А. Д. от имени врачей — участников программы “ПРОРЫВ”. Неконтролируемая артериаль-
5. ная гипертония — новые возможности в решении проблемы повышения эффективности лечения. Кардиология 2012; 2:29–35.)
6. Kobalava Zh. D., Kotovskaya Yu. V., Lukyanova E. A. on behalf of doctors — participants of the program CONSTANTA. Combined Therapy of Arterial Hypertension With the Fixed Combination of Perindopril Arginine/Amlodipine in Real Clinical Practice: the Organization and the Main Results of the Program CONSTANTA. Cardiology 2013; 6:25–34. (Кобалава Ж. Д., Котовская Ю. В., Лукьянова Е. А. от имени врачей-участников программы КОНСТАНТА. Комбинированная терапия артериальной гипертонии фиксированной комбинацией периндоприл А/амлодипин в реальной клинической практике: организация и основные результаты программы КОНСТАНТА. Кардиология
7. ; 6:25–34.)
8. Rothwell P. M., et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet. 2010; 375:895–905.
9. Sirenko Yu. N., Radchenko A. D. Dsyak G. V. et al. on behalf of doctors — participants of the program. Results of open study on evaluation of HT efficacy and tolerance of By-Prestarium in patients with newly diagnosed or uncontrolled on previous therapy hypertension. (Primary results of PERSPECTIVA study). Arterial hypertension 2010; 4 (12):7–19. (Сиренко Ю. Н., Радченко А. Д., Дзяк Г. В., от имени участников исследования. Результаты открытого исследования по оценке антигиПЕРтензивной эффективности и переносимости Би-Престариума у пациентов с артериальной гипертензией, вновь диагностированной или не КонТролИроВАнной предыдущей терапией (Первичные результаты исследования ПЕРСПЕКТИВА). Артериальная гипертония 2010; 4 (12):7–19).
10. Zhang Yi., Ly C., Yannoutsos A., et al. Effect of a fixed combination of Perindopril and Amlodipine on bloodpressure control in 6256 patients with not-at-goal hypertension: the AVANT’AGE study. Journal of the American Society of Hypertension 2013; 7:163–9.
11. Hatala R., Pella D., Hatalova K., S idlo R. Optimization of Blood Pressure Treatment with Fixed-Combination Perindopril/Amlodipine in Patients with Arterial Hypertension. Clin Drug Investig 2012; 32 (9):603–12.
12. Nagy V. 24 hour ambulatory blood pressure reduction with a perindopril/amlodipine fixed dose combination (PEARL-ABPM study). J Hypertens. 2011; 29 e-supplement A: e280.
13. Ahmod M. Efficacy and safety of a perindopril/amlodipine-based titration regimen on blood pressure goal achievement in hypertensive untreated patients or uncontrolled on monotherapy. J Hypertens. 2012; 30: e 439.
Review
For citations:
Ostroumova O.D., Guseva T.F., Bondarets O.V. Experience of using a fixed-dose combination of perindopril and amlodipine in the clinical practice settings: a real-world opportunity to increase antihypertensive therapy effectiveness. Russian Journal of Cardiology. 2013;(5):44-49. (In Russ.) https://doi.org/10.15829/1560-4071-2013-5-44-49
Views:
701
Email this article 